Evaluation of efficiency and safety for lascufloxacin drip infusion use for atypical pneumonia,including mycoplasma ,and legionella in the Saitama western area

Evaluation of efficiency and safety for lascufloxacin drip infusion use for atypical pneumonia,including mycoplasma ,and legionella in the Saitama western area - Evaluation of lascufloxacin drip infusion use for atypical pneumonia in the Saitama western area

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059212

Enrollment

Registered

2025-10-02

Start date

2025-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atypical pneumonia,including mycoplasma ,and legionella

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) the adult 2) the cases those were diagnosed as atypical pneumonia and will be LSFX will be administered 3) the case those will be accepted the switch therapy: intravenous to oral

Exclusion criteria

Exclusion criteria: 1) the cases those did not mycoplasma and legionella finally 2) the cases those have the contraindication for LSFX 3) the cases those have the too severe underlying diseases

Design outcomes

Primary

Measure	Time frame
Efficiency at end of treatment	—

Countries

Japan

Contacts

Public ContactMasafumi Seki

Saitama medical University International Medical center infectious diseases and infection control

sekimm@saitama-med.ac.jp042-984-4392

Outcome results